semaglutide gray market Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026 | Pharmaceuticals industry The future of the booming

Strategies to reduce side effects, such as slow dose escalation, unfortunately do not fully mitigate nausea, vomiting, and gastrointestinal (GI) distress, which are the primary reasons for treatment discontinuation ( 5 )

Theoretical considerations suggest Retatrutides triple-agonist mechanism might produce more robust effects on reward circuitry, similar to its enhanced weight loss efficacy compared to single-agonist medications

However, its worth saying that low (but not micro) doses could help a select few people who have unusually strong responses to these drugs

This article was produced by Tessa DiTirro for the Scripps News Group in Cleveland.

Most research on semaglutide focuses on its effectiveness for weight loss and blood sugar control on its own or with a regular diet